• Explore /
  • Poster
  • / Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

Abstract Poster

Authors

Arjun Balar

Arjun Vasant Balar

Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

Arjun Vasant Balar , Daniel E. Castellano , Peter H. O'Donnell , Petros Grivas , Jacqueline Vuky , Thomas Powles , Elizabeth R. Plimack , Noah M. Hahn , Ronald De Wit , Lei Pang , Mary Savage , Rodolfo F. Perini , Stephen Michael Keefe , Dean F. Bajorin , Joaquim Bellmunt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Prostate Cancer,Urothelial Carcinoma,Prostate Cancer

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02335424

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 284)

DOI

10.1200/JCO.2017.35.6_suppl.284

Abstract #

284

Poster Bd #

D21

Abstract Disclosures

Similar Posters

First Author: Jacqueline Vuky

First Author: Peter H. O'Donnell

First Author: Thomas Powles

First Author: Rafael Morales-Barrera